I think everyone reads too much into the timing of the report. Pre-market = GOOD and after hours = BAD? I don't think it matters at all with this type of company and at this stage of their product development. In pharmacy school, we learned that the average cost of getting a drug to market is about 500 million dollars. That's from the discovery of the chemical entity all the way to approval by the FDA and includes all the research and design and most importantly the cost of the years and years of clinical trials and manufacturing costs. ZGNX only has the one approved drug on the market and Sumavel isn't exactly a blockbuster drug. They probably haven't even recovered 10% of the costs they incurred to make Sumavel. So don't be suprised when the earnings look terrible! LOL... It just means that ZGNX has invested a ton of cash to actually produce the capsules in the last few months. Being the great investors that all of you are... you probably already knew all of this info and found this posting to be pointless, just like the other 99% of postings on this board. Good luck!!!